<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01514825</url>
  </required_header>
  <id_info>
    <org_study_id>150-CL-026</org_study_id>
    <nct_id>NCT01514825</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly Subjects</brief_title>
  <official_title>YM150 Clinical Pharmacology Study - Repeated Oral Administration to Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and plasma concentration change of YM150
      after repeated administration to healthy elderly male and female subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of YM150 assessed by its plasma concentration change</measure>
    <time_frame>for 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of YM150 assessed by its plasma concentration change</measure>
    <time_frame>for 7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the blood coaggregation indexes such as PT(INR), aPTT and FXa</measure>
    <time_frame>for 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the incidence of adverse events, vital signs, 12-lead ECG and labo-tests</measure>
    <time_frame>for 7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy Elderly Subject</condition>
  <condition>Pharmacokinetic of YM150</condition>
  <arm_group>
    <arm_group_label>YM150 low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>YM150 middle dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>YM150 high dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YM150</intervention_name>
    <description>oral</description>
    <arm_group_label>YM150 low dose group</arm_group_label>
    <arm_group_label>YM150 middle dose group</arm_group_label>
    <arm_group_label>YM150 high dose group</arm_group_label>
    <other_name>darexaban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, as judged by the investigator or sub-investigator based on the results of
             physical examinations and all tests

          -  Body weight: male: ≥45.0 kg, &lt;85.0 kg; female: ≥40.0 kg, &lt;75.0 kg

          -  BMI (at screening): ≥17.6, &lt;30.0

        Exclusion Criteria:

          -  Use of any other investigational drug in another clinical study or a post-marketing
             clinical study within 120 days before the administration of the study drug

          -  Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or
             blood components within 14 days before the screening assessment.

          -  Any surgical intervention (including tooth extraction) or trauma within 90 days before
             hospitalization until the administration, or plan of any surgical intervention within
             10 week after the final administration

          -  A deviation from the normal reference range of blood pressure, pulse rate, body
             temperature, or 12-lead ECG

          -  PT or aPTT on blood coagulation tests outside the upper or lower reference limits (PT:
             9.9 to 15.4 sec.; aPTT: 22.5 to 49.5 sec.)

          -  Upper gastrointestinal disease (e.g. nausea, vomiting, stomachache) within 7 days
             before the study

          -  Concurrent or previous hepatic disease (e.g. viral hepatitis, drug-induced liver
             injury)

          -  Concurrent or previous heart disease (e.g. congestive heart failure, angina pectoris,
             arrhythmia requiring treatment)

          -  Concurrent or previous respiratory disease (e.g. serious bronchial asthma, chronic
             bronchitis; except for a history of childhood asthma)

          -  Concurrent or previous renal disease (e.g. acute renal failure, glomerulonephritis,
             interstitial nephritis; except for a history of calculus)

          -  Concurrent or previous malignant tumor

          -  Excessive smoking or drinking habit [measure of &quot;excessive&quot;: alcohol: average 45 g/day
             (a 633 mL bottle of beer contains 25 g of alcohol, and 180 mL of Japanese sake
             contains 22 g of alcohol), smoking: average 20 cigarettes/day]

          -  Previous treatment with YM150
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2012</study_first_submitted>
  <study_first_submitted_qc>January 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2012</study_first_posted>
  <last_update_submitted>January 23, 2012</last_update_submitted>
  <last_update_submitted_qc>January 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>YM150</keyword>
  <keyword>Plasma concentration</keyword>
  <keyword>darexaban</keyword>
  <keyword>Healthy elderly subject</keyword>
  <keyword>Pharmacokinetics of YM150</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darexaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

